Categories
Digital Health MedTech

Harvest Now, Decrypt Later: Why Healthcare Must Go Post-Quantum Today

Harvest now, Decrypt later - post-quantum healthcare - medtech security

The Threat

Healthcare runs on trust — but its digital backbone is fragile. A sufficiently powerful quantum computer will run Shor’s algorithm, breaking RSA and elliptic curve cryptography. That means everything from EHRs to connected pacemakers is at risk.

And the danger isn’t hypothetical. Adversaries are already engaging in “Harvest Now, Decrypt Later” (HNDL) — collecting encrypted medical data today to crack open once quantum machines catch up. Health records are especially valuable because they must remain confidential for decades, often a century.

The Urgency

The US NIST finalised the first post-quantum cryptography (PQC) standards in 2024, including CRYSTALS-Kyber for key establishment and CRYSTALS-Dilithium for signatures. The EU has yet to mandate PQC explicitly, but under GDPR’s requirement for “appropriate technical measures”, regulators will likely interpret compliance as requiring migration.

Medtech and pharma firms cannot afford to wait. Migration is not a patch but a multi-year transformation: inventorying cryptographic assets, building crypto-agile architectures, and upgrading every system from EHRs to clinical trial platforms.

The European Edge

Europe is not passive. The EuroQCI initiative aims to build a pan-European quantum communication infrastructure based on quantum key distribution (QKD) — an ultra-secure backbone for critical sectors, healthcare included.

But PQC migration remains the urgent first step. Quantum-secure comms infrastructure is years away; vulnerable encryption is a present reality.

Strategic Takeaway

For European healthcare organisations:

  • Start the migration now: waiting until Y2Q is too late.
  • Prioritise PQC vendors and services: the “picks and shovels” of the quantum security gold rush.
  • Engage boards early: GDPR fines (4% of global turnover) make PQC a board-level risk.

Quantum computing’s promise in drug discovery may take a decade. Its threat to healthcare cybersecurity is here today. The winners will be those who treat post-quantum cryptography not as R&D, but as critical infrastructure.

Categories
Digital Health MedTech

Europe MedTech & Digital Health Weekly Brief (Week of August 30–September 5, 2025, #5)

Hospitals want evidence, investors want traction: this week mixed the two: GI diagnostics, insulin delivery, genomics M&A. And sprinkled in fresh CE marks for surgical robots.

People on the move

Data4Life (DE), a digital health nonprofit backed by SAP founder, Hasso Plattner, appoints Dr. Ben Illigens as CEO to steer its health data and research initiatives. Data4Life is building open source platform Data2Evidence, which is based on the international OMOP data model.

“We are at a turning point where digital technologies are fundamentally transforming research and care. My goal is to strengthen Data4Life as a bridge between clinical research, technology, and practice,”
Dr. Ben Illigens.

Lottie (UK): George Hadjigeorgiou, cofounder of ZOE, a personalized nutrition health company, joins the board of Lottie as NED, signaling deeper crossover between consumer health and eldercare ops. Lottie is a UK’s marketplace for care homes and care services.

Money flows

Kaleido Insulin Pump visualisation - Source: https://hellokaleido.com/

ViCentra (NL) — $85M Series D; insulin patch pump maker (Kaleido) fuels next-gen device development and scale-up.  Round was led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations.

Cyted Health (UK) — €37.5M Series B; GI molecular diagnostics to improve early detection and prevention of oesophageal cancer. Round aims to expand US commercialization while consolidating NHS footprint. Investment led by EQT Life Sciences, Advent Life Sciences and British Business Bank with continued support from existing investors Morningside and BGF.

ArcaScience (FR): $7M round led by The Moon Venture; AI “benefit–risk” intelligence platform for life-sciences R&D to clean, link and query messy evidence.

Aiomics (DE) — €2M pre-Seed; clinical-grade AI agents to reduce clinical documentation burden and improve care pathways.

M2Care (FR): €26M venture-studio raise from Bpifrance’s FTA2 fund to create/develop eight healthtech projects. Other investors in M2Care are Mérieux Développement (who actully created this incubator), Institut NAOS des Sciences de la Vie, Crédit Agricole Centre-Est. 

SeqOne (FR) aquired Congenica (UK), on undisclosed terms.
This merger creates a larger AI-powered genomics software group with strong UK presence.

On the press

One thing to remember

Evidence-first commercialisation is back: capital flowed to diagnostics and chronic-care delivery while robotics snagged CE marks. A cross-border genomics deal underlined that European buyers will pay for software that shortens time-to-impact. If you’re fundraising, pair outcomes data with a path to multi-market reimbursement; if you’re buying, look for software that accelerates clinical workflows, not just visibility.

Categories
MedTech Pharma Marketing

Omnichannel Marketing Metrics That Actually Deliver in Pharma & MedTech

Omnichannel Marketing KPI template for pharma and medtech

Omnichannel is non‑negotiable in pharma and medtech marketing. In recent study 97% of industry leaders say it’s vital. Yet execution remains consistently fragmented, and fewer than half even measure ROI regularly. That’s the mission-critical gap any marketer needs to bridge. I am here to help.

Benchmarks That Put ROI in Frame

1. Revenue Uplift
When omnichannel is done right, top performers record over 15% revenue gains.
Many report 5–15% lifts, particularly where personalised, multi-channel approaches are scaled.

2. Marketing Efficiency Gains
Pharma innovators using hybrid commercial models see 10–40% improvements in marketing efficiency—faster time to market and lower cost per outcome.

3. Investment Signals
Companies allocate 10–15% of their promotional and advertising budget to omnichannel solutions—evidence of meaningful investment.

4. Strategic Capability Gaps

As BCG study shows medtech and biopharma marketing leaders identifycritical gaps:

  • 30% lack a clear omnichannel strategy, especially SMEs.
  • 90% cite data silos as a major barrier; only 10% have fully integrated data systems.
  • Only 7% are broadly leveraging AI/GenAI in omnichannel.
  • Less than 17% review performance metrics more than monthly.

Pharma and MedTech Omnichannel Marketing KPI Template

Use this template as your go-to scorecard in dashboards or meetings. Tweak thresholds to match your maturity stage.

MetricDescription / Use CaseBenchmark Range
Revenue Uplift (%)Compare current period vs. baseline revenue5–15%, top performers >15%
Marketing Efficiency Gain (%)Cost savings, time-to-market improvements10–40%
Revenue Growth Attribution (%)Portion of growth tied directly to omnichannel efforts≥5%
Budget Allocation (%)% of total ad/promo spend, dedicated to omnichannel10–15%
Data Integration MaturityInternal scale (1–5) or Yes/No for integrated platformsFull integration
AI/GenAI Adoption Rate% workflows using AI-driven personalisation≥7%
ROI Tracking CadenceFrequency of KPI reviews (daily, weekly, monthly)Target: Monthly or finer
Next Best Experience Adherence Rate% of next best-experience suggestions followedAim for >60%
HCP Satisfaction (NPS)Net Promoter Score of omnichannel engagementTop quartile

How to Use This Template as a Tool for Change

  1. Start with the high-impact metrics revenue uplift, efficiency gain, budget share. Then layer in Omnichannel Marketing maturity and AI adoption.
  2. Set realistic benchmarks: for emerging teams aim at the 5–10% uplift band; for execution-capable teams push for 15%+.
  3. Track performance monthly those who review less frequently (only 17% do so monthly or more often) risk losing momentum.
  4. Address barriers consciously if AI or data integration scores are low, plan targeted investments or pilot programs.
  5. Use Next Best Experience adherence as a cultural pulse. Low compliance signals change management, not tech, is the bottleneck.

Final Take

Omnichannel in pharma and medtech is a strategic advantage—unless you fail to measure it. Now you have hard benchmarks and a KPI template proven in the field. Use them to bridge the gap between ambition and impact.

Metrics aren’t optional: they transform omnichannel from buzzword to business model.

Categories
Digital Health MedTech

Pharma’s Quantum Bet: Can Qubits Fix Drug R&D’s 90% Failure Rate

Quantum computing in pharma drug discovery R&D

The Promise

Pharma spends billions on R&D only to see 90% of drug candidates fail in trials. At the heart of the problem: chemistry is a quantum system, but we’ve been simulating it with classical approximations. Quantum computing, in principle, can simulate molecules and protein folding with physics-native precision, potentially cutting years and billions from discovery pipelines.

The Reality

We are not about to quantum-simulate an entire antibody. Today’s quantum machines remain noisy, small, and fragile. The most credible progress has come from hybrid models, where quantum handles a computational bottleneck and classical HPC does the rest. For example:

  • Cleveland Clinic & IBM: Predicted Zika virus protein fragments more accurately than AlphaFold using a hybrid quantum-classical framework (Cleveland Clinic).
  • Japan Tobacco & D-Wave: Used quantum annealing to train generative AI, producing more “drug-like” molecules than classical methods (MedPath).
  • Biogen & Accenture: Quantum-enabled molecular comparison delivered richer structural insights than classical screening (Accenture).

Each success is narrow, but collectively they show a pragmatic pattern: don’t replace classical, augment it.

The European Edge

Europe is well-positioned. Startups like Pasqal (France) are already running protein hydration analyses on neutral-atom quantum computers (Qubit Pharmaceuticals). The Quantum Technologies Flagship (€1bn over 10 years) funds such projects (EU Commission). Combined with Horizon Europe grants and EuroHPC’s hybrid supercomputers, pharma here has access to sovereign infrastructure and public co-funding that US peers often lack.

Strategic Takeaway

For European pharma and biotech:

  • Think long-term: validated drug design use cases are 5–15 years out (Roche).
  • Back hybrids: near-term ROI lies in workflows where quantum complements AI, not replaces it.
  • Partner early: collaborations with quantum startups and HPC centres are essential to de-risk.

Quantum won’t cure R&D inefficiency overnight. But when 9 in 10 candidates still fail, even a narrow, validated quantum edge could mean the difference between another failed trial and Europe’s next blockbuster drug.

This content has been enhanced with GenAI tools.

Categories
Digital Health MedTech

Europe MedTech & Digital Health — Weekly Brief (Week of August 23–29, 2025, #4)

OrganOx metra transport. Source: OrganOx website

This week’s highlights: a landmark UK medtech exit, a €403 million EU funding boost for AI-powered devices, and strategic momentum building across Europe for medtech commercialization. Otherwise it seems we are on annual leave.

People on the move

No newly reported high-level hires, board moves, or fund leadership changes in the European medtech/digital health sector this week.

Money flows

One thing to remember

Founders: now is the time to align innovation pipelines with EU priorities—combine clinical validation and AI integration with a clear path to strategic M&A to attract both Brussels funding and corporate buyers.

Categories
MedTech

€200 Million for Ortivity: Why Outpatient Orthopaedics Is Europe’s Quiet MedTech Power Play

Ortivity logo.

€200 million. Not a sum we see every day in European HealthTech, especially outside AI hype-cycles. Munich-based Ortivity broke the mould—raising a mega‑round led by Apheon, with new capital from Unigestion, allowing existing shareholders a partial exit.

What is Ortivity?

If you are not living in Germany, you probably never heard about it. Founded in 2022 Ortivity has over the past four years bacame one of Germany’s most prominent outpatient healthcare platforms. It operates over 100 sites across three regional clusters in Germany, offering a full spectrum of orthopaedic services, including diagnostics, anaesthesia, surgery, prevention, and aftercare.

Ortivity’s physician partnership model and emphasis on clinical excellence is unique. It is owned equally by physicians and capital providers.

Leadership & Founders: Meet the Faces Behind the Platform

Founding Doctors

Ortivity was launched in 2022 through a collaboration between Dr med Reinhard Wichels and Apheon, along with a network of leading physicians. Wichels framed the vision from day one as “physician networks closing gaps in access and quality,” a quote that still anchors the company’s ethos.

New Co-CEO: Dr Michael Thorwarth

Joining Ortivity as co‑CEO on 1 June 2025, Dr Michael Thorwarth brings dual expertise in medicine (MKG surgery), healthcare management (MBA), and consulting. Prior to Ortivity, he was a Partner at BCG, CEO at DEIN DENTAL, and Group CEO at Ergéa Group, a pan-European player in oncology, radiology and diagnostics.

Why This Round Matters

  • Mega‑scale in a cautious market: A €200 million deal in EU HealthTech is rare. It signals renewed investor confidence in service-oriented MedTech, beyond devices or AI.
  • Leadership reflects intent: Bringing on a seasoned strategist with transformation credentials like Thorwarth indicates clear intent to scale fast and structure for international growth.
  • Physician-led, but platform-focused: Ortivity’s buy‑and‑build model expanding into regional orthopaedic clusters in NRW, Bavaria, Baden-Württemberg shows a credible path to consolidation in a fragmented EU market

The Bigger Picture for EU MedTech

  • From cottage to platform: Europe’s MedTech strength has been in manufacturing devices, but scaling integrated care platforms remains elusive. Ortivity’s rise suggests that’s beginning to change.
  • Orthopaedics as export vertical: With ageing demographics, musculoskeletal care is a high‑demand field. A platform that delivers standards, scale, and efficiency across borders has global potential.
  • Private equity getting serious: Apheon remains the lead investor, indicating commitment and patience. With Unigestion joining, it’s clear the capital strategy is long‑term, not flip‑and‑sell

Takeaway

This isn’t just another €200 million HealthTech round. It’s a watershed moment for European MedTech. A proof that physician‑led outpatient platforms can attract serious capital, build organisational muscle and potentially export a scalable model.
And, ironically, the biggest disruption in health might come not from injecting AI into everything, but from getting people back on their feet: efficiently, compassionately, and at scale.

Categories
Digital Health

Quantum Computing in Healthcare: Breakthrough or Expensive Distraction?

Quantum Computing in Healthcare - IBM Quantum One in Cleveland Clinic.
Quantum Computing in Healthcare - IBM Quantum One in Cleveland Clinic. Source: Cleveland Clinic

Quantum computing is the latest shiny object in healthcare IT. Headlines trumpet its ability to solve the unsolvable, to accelerate drug discovery, and to personalise medicine at a level classical AI can only dream of. The reality, however, is a little noisier, literally. In 2025, we are firmly in what researchers call the NISQ era. NISQ stands for Noisy Intermediate-Scale Quantum, where machines are powerful but error-prone, and purely quantum solutions remain more PowerPoint than product.

Why the Hype?

The hype is not entirely misplaced. Biology and chemistry are inherently quantum systems. Simulating how a drug molecule interacts with a protein is not just hard for classical supercomputers; it’s unnatural. Classical methods rely on approximations. Quantum computers, in theory, model these interactions directly. That’s why pharma giants are experimenting: Cleveland Clinic has an IBM Quantum System One installed on-site, the first dedicated to healthcare. Early results show hybrid quantum-classical workflows can outperform DeepMind’s AlphaFold on narrow protein-folding tasks.

Why the Reality Check?

The breakthroughs so far are niche, fragile, and deeply dependent on clever hybridisation with classical HPC. A systematic review of nearly 5,000 research papers (2015–2024) found no consistent evidence that quantum machine learning currently beats classical methods for healthcare. Many proofs of concept run in “noiseless simulations” that collapse when ported to real hardware. And the qubit counts remain too low for practical drug-scale simulations.

Even in genomics, often billed as the killer app for quantum computing, the maths doesn’t add up. Encoding billions of data points into qubits introduces overhead that wipes out theoretical speedups. For now, Europe’s quantum advantage is likely to remain incremental: narrow use cases, tightly scoped, with the real value in hybrid algorithms.

Why Europe Must Care Now: Security

The most immediate and non-negotiable issue is not discovery but security. A sufficiently powerful quantum machine will break today’s public-key cryptography (RSA, ECC). Healthcare is especially exposed, with decades-long data sensitivity. The threat isn’t theoretical, it’s already here. Adversaries are harvesting encrypted medical data today, betting on decrypting it later (“Harvest Now, Decrypt Later”). The US NIST has finalised post-quantum cryptography standard (CRYSTALS-Kyber, CRYSTALS-Dilithium) in 2024. GDPR’s mandate for “appropriate technical measures” means EU hospitals, medtech, and pharma firms will have to migrate.

Strategic Takeaway

Quantum computing in healthcare is not snake oil, but nor is it a silver bullet. In the short term, Europe’s smartest bets are twofold:

  • Defensive: Migrate to post-quantum cryptography before Y2Q arrives.
  • Pragmatic: Invest in hybrid models where quantum adds value to a specific pain point, not the whole pipeline.

Quantum may indeed change healthcare. But for now, the winning strategy is less “revolution at the bedside” and more “upgrade in the back office.” The future belongs to those who can separate signal from quantum noise.

This content has been enhanced with GenAI.

Categories
MedTech

OrganOx’s $1.5B Exit and Europe’s €403M MedTech Push: A Blueprint for Start-Up Success

OrganOx metra transport. Source: OrganOx website

Forget IPO hype. Europe’s MedTech scene is quietly reinventing exit strategies. The recent blockbuster OrganOx deal shows that patient-growth capital and global acquirers, not public markets, may set the real pace for scaling life-saving innovation.

OrganOx’s $1.5B Exit: A MedTech Precedent in a Quiet Market

Oxford-based OrganOx, a university spin‑out, has secured one of the UK’s largest MedTech exits, a $1.5 billion acquisition by Terumo. The deal delivered a 10× return for BGF, one of the UK’s most active investors. OrganOx’s technology, automated liver perfusion, has already supported over 6,000 transplants worldwide. In layman terms, it allows fors fully automated, easy-to-use preservation of the donor organ in a functional state for up to 24 hours.

In a market where IPOs have gone quiet, this deal sets a new precedent: high-value, clinically proven MedTech start-ups don’t need to chase the volatility of public markets to deliver impact and returns.

Europe’s MedTech Funding Engine: A Public‑Private Lever

The European Commission has approved a €403 million funding IPCEI programme for MedTech SMEs, with a focus on digital health and AI-enabled devices. The package is expected to attract €826 million in private capital and create 800 jobs across Europe.

For startups, this funding represents more than a financial lifeline: it’s a validation that EU policy is actively supporting MedTech innovation and aiming to rebalance Europe’s lagging venture ecosystem.

What This Means for Start-ups? Beyond IPOs to Real Outcomes

  • Exit without IPO: OrganOx proves that acquisition can be just as transformative as a listing.
  • Policy-driven growth: Founders should align their pipelines with EU funding priorities to maximise non-dilutive leverage.
  • Execution over hype: Europe rewards clinical validation and scalable access models—not moonshot projections.

Startups should design strategies that are M&A ready while embedding pathways to tap into EU-backed scaling opportunities.

Implications for Strategy and Investors

  • For founders: Patient growth capital and regulatory navigation matter more than vanity valuations. Position your business for strategic buyers who can unlock global reach.
  • For investors: The OrganOx exit underscores the value of holding through scale. In a funding environment tilted towards policy-supported growth, long‑term bets on MedTech SMEs can deliver double‑digit returns.

Conclusion

OrganOx isn’t just a headline; it’s a guidepost. In Europe’s MedTech world, execution and ecosystem alignment outperform aspiration for the trading floor. The lesson? IPO dreams may dominate headlines, but the real exits are happening elsewhere.

Categories
Digital Health MedTech

Europe MedTech & Digital Health — Weekly Brief (Week of Aug 16–22, 2025, #3)

AI meets approvals, mental health consolidates, and early-stage device builders get fuel — a tidy week for cardiology/ophthalmology AI, workflow rollouts, and surgical tools.

People on the move

CMR Surgical: Chris O’Hara joins as Commercial President & GM (U.S.) to drive Versius robot expansion following FDA authorization; signals Cambridge-based CMR’s acceleration of global go-to-market. Mr. O’Hara brings experience at Intuitive Surgical (a company that builds DaVinci that Versius robot is challenging) and Globus Medical (specialists in spine sugery devices), his appointment is a strategic bet from CMR Surgical.

Money flows

Nami Surgical (Glasgow, UK): $10M, Series A (opened); developing a mini ultrasonic scalpel for robotic surgery. Proceeds support product development and commercialization prep. Tech from Nami addresses a critical unmet need in the field. Ultrasonic scalpels, which use high-frequency vibrations to simultaneously cut tissue and cauterise blood vessels, are indispensable tools in modern minimally invasive surgery. What they have is 90% smaller than available competitors.

Mindler (Sweden) acquires ieso Digital Health UK on undisclosed terms; creates a cross-border digital mental health platform spanning Nordics & UK buyers (employers, insurers, public payers). As there is an urgent need to address crisis of mental health and lack of (human) specialists, platforms such us Mindler and ieso are indispensable.  Mindler is acquiring only ieso’s UK-based telecare services business, which is responsible for direct patient care delivery to the NHS. The parent company, ieso, will remain an independent entity pivoting to focus on the development and commercialisation of its evidence-based clinical AI platform, Velora, with an initial focus on the US market.

On the press

• ZEISS lands CE mark for CIRRUS PathFinder: integrated AI decision-support for OCT that flags abnormal macular B-scans and improves OCTA visualization; EU-ready software update/licence.

• Femasys secures UK MHRA approval for FemBloc: non-surgical, in-office permanent contraception; follows the company’s recent CE mark and advances European commercialization.

• Affidea x Skin Analytics: pan-European partnership to deploy Class III CE-marked AI dermatology (DERM – Deep Ensemble for the Recognition of Malignancy) across sites, starting in Romania and Lithuania with Greece next.

One thing to remember The EU’s AI-in-diagnostics momentum is real: new CE/MHRA greenlights (ZEISS, FemBloc) are pairing with deployment deals (Affidea × Skin Analytics), while funding still finds focused hardware/robotics and safety wearables (Nami Surgical, SIT). Founders: bring regulatory-grade proof and a crisp rollout plan.

This content has been enhanced with GenAI tools.

Categories
Pharma Marketing

Veeva and IQVIA Call Truce: From Lawsuit to Data Integration

Veeva - IQVIA lawsuit ends

Eight years of lawsuits. Zero damages paid. And now, a partnership.

After nearly a decade of courtroom brawls, Veeva and IQVIA have finally ended their long-running legal dispute. On 18 August 2025, the rivals dismissed all claims with prejudice (read: permanently), and instead signed multi-year agreements to integrate their data and software platforms

From Courtroom Drama to Cooperation

  • 2017: IQVIA sued Veeva for alleged trade secret theft and data misuse [IQVIA vs Veeva case filing].  
  • Veeva countered, accusing IQVIA of antitrust abuses and blocking customer data access ([Veeva statement].
  • Years of litigation followed, with motions, sanctions, and counterclaims clogging US federal courts.  

Fast forward to 2025: instead of exchanging damages, both firms agreed to exchange data. All lawsuits are dropped, no money changes hands (beyond Veeva’s $31m legal bill under outcome-based fees, and the rivalry shifts from courtroom to boardroom.  

The Resolution: What’s in the Deal?

The truce is more than symbolic, it’s operational:  

  • Third-Party Access (TPA): IQVIA’s data can now flow into Veeva platforms (Network, Nitro, AI), while Veeva’s data is unlocked for IQVIA.  
  • Clinical Collaboration: IQVIA joins the Veeva Clinical Data Partner program, plugging into Veeva’s Clinical Suite (EDC, SiteVault, etc.) for faster trial builds and smoother data delivery.  
  • AI & Tech Integration: IQVIA signs onto Veeva’s Technology, AI, and Services Partner Programs.  

Translation: instead of duplicating systems and blocking interoperability, both firms now enable cross-platform data use exactly as biopharma customers (and regulators) have been demanding.  

Why It Matters for Europe

European life sciences has long struggled with fragmented data flows across GDPR-guarded patient datasets, MDR/IVDR compliance, and DiGA-like digital health pathways.  

This resolution is strategically significant because:  

  • Interoperability accelerates adoption: Pharma won’t need to choose between data suppliers—systems finally talk to each other.  
  • Clinical trials speed up: CROs and sponsors can cut timelines by integrating EDC and analytics directly.  
  • Commercialisation gains efficiency: Omnichannel marketing becomes more data-driven when IQVIA real-world data meets Veeva’s CRM and AI.  

Eight years of legal warfare ended not with a knockout, but a handshake. The life sciences sector gets what it wanted all along: a functioning data ecosystem where Veeva and IQVIA finally play on the same team. 

And if you’re tracking commercialisation playbooks, revisit our piece on omnichannel pharma and medtech strategy; this deal just made the data plumbing a lot easier!  

This content has been enhanced with GenAI.